GlassScriptPhysician profile
Janani Rangaswami
NPI 1275748626
$152,267.23
in general payments reported to CMS, 2019-2025
13 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $11K · 2021: $5,395 · 2022: $32K · 2023: $51K · 2024: $9,953 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,935.00 |
| Travel and Lodging | $24,487.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,439.74 |
| Food and Beverage | $789.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $50,557.99 | 2022-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,272.41 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $25,172.50 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18,368.06 | 2023-2025 | |
| Eli Lilly and Company | $9,315.00 | 2021-2023 | |
| Edwards Lifesciences Corporation | $6,176.25 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $4,715.59 | 2020-2021 | |
| Abbott Laboratories | $4,490.00 | 2019-2020 | |
| Rockwell Medical, INC. | $2,100.00 | 2020 | |
| Fresenius USA Marketing, INC. | $32.08 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $25.57 | 2019 | |
| Daiichi Sankyo INC. | $24.08 | 2020 | |
| Amgen INC. | $17.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janani Rangaswami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.